ASO Author Reflections: Neoadjuvant Treatment for Melanoma-Where Are We Now?

Affiliations

¹ Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Cimarron.sharon@pennmedicine.upenn.edu.
² Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Comment

Cimarron E Sharon et al. Ann Surg Oncol. 2022 Dec.

. 2022 Dec;29(13):8501-8502.

doi: 10.1245/s10434-022-12308-3. Epub 2022 Jul 26.

¹ Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Cimarron.sharon@pennmedicine.upenn.edu.
² Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

No abstract available

Comment on

Educational Review: Neoadjuvant Approaches to Melanoma.
Sharon CE, Karakousis GC. Sharon CE, et al. Ann Surg Oncol. 2022 Dec;29(13):8492-8500. doi: 10.1245/s10434-022-12224-6. Epub 2022 Jul 18. Ann Surg Oncol. 2022. PMID: 35849287 Review.

1. Sharon CE, Karakousis GC. Educational review: neoadjuvant approaches to melanoma. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12224-6 . - DOI - PubMed
1. Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–61. https://doi.org/10.1038/s41591-018-0198-0 . - DOI - PubMed
1. Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–60. https://doi.org/10.1016/S1470-2045(19)30151-2 . - DOI - PubMed
1. Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178–88. https://doi.org/10.1038/s41591-022-01851-x . - DOI - PubMed
1. Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301–9. https://doi.org/10.1038/s41591-020-01188-3 . - DOI - PubMed